Please select your page

Knight Therapeutics Inc. Announces Election of Directors

MONTREAL, QUEBEC – (June 4, 2015) - Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”) announced today that each director nominee listed in the Management Information Circular dated May 1, 2015 was elected as Director of the Company during the Annual Meeting of the Shareholders held in Montréal, Québec.

The details of the election are as follows:

DIRECTOR Nominee

Outcome

Votes For

% For

votes Withheld

% Withheld

James C. Gale

Elected

54,781,722

98.04%

1,097,731

1.96%

Jonathan Ross Goodman

Elected

55,871,853

99.99%

7,600

0.01%

Robert N. Lande

Elected

55,016,826

98.46%

862,627

1.54%

Ed Schutter

Elected

55,869,703

99.98%

9,750

0.02%

Sylvie Tendler

Elected

55,792,502

99.84%

86,951

0.16%

 

The results of the final votes regarding all matters subject to a vote during the Annual Meeting will be made available on SEDAR (www.sedar.com).

About Knight Therapeutics Inc.:

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight's shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the Company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for the Company and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in the Company’s Annual Report and in the Company’s Annual Information Form for the year ended December 31, 2014. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. 

For further information please contact: 

Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
Tel: 514-484-GUD1 (4831)
Fax: 514-481-4116
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.gud-knight.com

Buy now

You can now buy this awesome Joomla Theme directly on Themeforest for a really low price for this awesome and stunning Joomla product!

Nulla vitae elit libero, a pharetra augue. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porta sem malesuada magna mollis euismod. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Nulla vitae elit libero, a pharetra augue.

BUY NOW ON THEMEFOREST

×

Login

Please login using your credentials recived by email when you register.

  or   Create an account

Forgot your password? |  Forgot your username?

×

Register now


I'm a small Introtext for the Register Module, I can be set in the Backend of the Joomla WS-Register Module.



  or   Login
×